To assess the clinical relevance of the immunophenotypes identified in our preclinical model, we conducted a comprehensive analysis of RANKL (Tnfsf11) and OPG (Tnfrsf11b) expression in relation to CD4+ T and B cell subpopulations across breast cancer subtypes using the TIMER database, with a focused evaluation of the BRCA-Basal group (n = 191), which includes TNBC. This evidence concerns the gene CD4 and breast carcinoma.